Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharmaceutical company Crucell has signed a non-exclusive Star research and commercial licensing agreement with Centocor, a US-based biopharmaceutical company, for the production of monoclonal antibodies. Financial details of the agreement were not disclosed.
Subscribe to our email newsletter
Star technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is reported to be effective for the production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology and the Chinese hamster ovary cell line.
According to Crucell, Star technology contains genetic elements, called Star elements that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology reportedly has the potential to increase production yields, thereby reducing production costs.